News
The day at a glance · 4 min read
Mood · Risk-Off
-35
Sentiment, −100 to +100
BMY Stock Decline
2%-2%
Tempus AI Gain
6%+6%
LLY Richmond Investment
$5B
Key driverClinical trial safety events and slowing medical device demand offset regulatory wins and managed care strength
Daily briefHealthcare· Money365.Market AI ·

Healthcare Dips on Trial Safety, Surgical Robot Slowdown

Bristol Myers patient death and Intuitive's U.S. growth deceleration weigh on sector; AbbVie wins Crohn's approval, UnitedHealth rides earnings beat

Healthcare Market Overview

Bearish
01BMY▼ -2.41%
Healthcare stocks declined Friday afternoon, with the NYSE Healthcare Index dropping 1.2% as clinical trial safety concerns and slowing medical device demand weighed on sentiment. The sector faced headwinds from Bristol-Myers Squibb ($BMY) trial developments and Intuitive Surgical ($ISRG) growth deceleration, while managed care strength from UnitedHealth ($UNH) and regulatory wins at AbbVie ($ABBV) provided limited offsets.

Big Pharma & Biotech

Neutral

LLY 30-Day Return

11.67%+11.67%

LLY YTD Gain

20.95%+20.95%

Gilead Settlement

$45M
01BMY▼ -2.41%
Bristol-Myers Squibb ($BMY) stock fell 2% after a patient death in its early multiple sclerosis CAR T trial, with the death occurring after the study's data cutoff in patients with highly active relapsing MS. The company separately announced a licensing agreement with Tempus AI for oncology data through 2031 and use of its Lens AI platform, with Tempus shares gaining 6% on the returning customer commitment.
02LLY▼ -2.54%
Eli Lilly ($LLY) broke ground on a $5 billion manufacturing hub near Richmond, Virginia, a fully integrated site for active ingredients and finished antibody drug conjugate medicines, as the company posted a 30-day share price return of 11.67% and year-to-date gain of 20.95%. Goldman Sachs reset the company's 12-month stock price target ahead of earnings, with Wall Street expecting strong numbers but the firm indicating one figure will determine market reaction.
03ABBV
AbbVie ($ABBV) secured FDA approval for a subcutaneous induction regimen for SKYRIZI (risankizumab-rzaa) for adults with moderately to severely active Crohn's disease, allowing patients to start treatment at home with an on-body injector induction pack followed by maintenance doses every eight weeks. The approval expands treatment options for a condition requiring long-term management and reinforces the company's position as it navigates the Humira patent cliff.
04GILD
Gilead Sciences ($GILD) reached a $45 million settlement with Texas Attorney General Ken Paxton, resolving claims that the company offered illegal incentives to medical providers to prescribe its drugs over competitors' medications. The settlement was announced October 22 with support from The Lanier Law Firm, which cited decades of holding pharmaceutical companies responsible for dangerous products and unlawful business practices.

MedTech & Devices

Bearish

ISRG Stock Decline

6%-6%
01ISRG▲ +1.90%
Intuitive Surgical ($ISRG) shares fell 6% after U.S. growth for the company's da Vinci surgical robot system slowed to the lowest level seen since COVID, marking a significant deceleration in the core domestic market that has historically driven the company's expansion. The slowdown raises questions about hospital capital equipment budgets and procedure volume trends in the company's largest market.

Health Insurance & Managed Care

Bullish

UNH Weekly Gain

11%+11%
01UNH
UnitedHealth ($UNH) stock rose 11% in a week through Tuesday's close after a third-quarter beat and raised 2026 outlook for adjusted EPS of at least $20.50, with the company citing discipline and execution. The strong quarter and guidance lift demonstrate the managed care giant's ability to navigate medical cost pressures and maintain margin discipline in a challenging reimbursement environment.

M&A Activity

Neutral
01JNJ
Johnson & Johnson ($JNJ) merger talks with Smith & Nephew to combine with J&J's orthopedics division collapsed over a leadership dispute, ending discussions that would have created a major orthopedics consolidation. The breakdown suggests continued challenges in large-scale medical device M&A where integration complexities and management structure can derail strategic combinations.

Emerging Markets & Weight Loss

Bullish

EM Weight Loss Sales Forecast

$22B
01LLY▼ -2.54%
JP Morgan expects emerging market weight loss drug sales to reach $22 billion, highlighting the growth potential for GLP-1 medications beyond developed markets as Eli Lilly ($LLY) and competitors expand global distribution. The forecast underscores how obesity treatment is becoming a worldwide pharmaceutical opportunity rather than a developed-market phenomenon.

Oncology & Cancer Therapeutics

Neutral

Iovance ORR

62.5%
MRK
01
Iovance's melanoma therapy showed promising 4-year data with Phase 2 results demonstrating an objective response rate of 62.5%, with retail investors speculating an acquisition could occur before 2027-end. The durable response data strengthens the cell therapy's commercial profile and makes it a potential takeover target for larger oncology players seeking to expand their immuno-oncology portfolios.
02
Merck and Moderna diverged on cancer vaccine results as investors digested early release data, though the articles did not detail specific efficacy figures or whether the companies view the program as viable going forward. The market reaction suggests uncertainty about the partnership's development path and commercial potential.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy